Can a single injection of ART105 safely alter key body markers?
NCT ID NCT07748026
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This early-stage trial aims to see if a single injection of ART105 is safe and tolerable in healthy adults aged 18 to 55. It also looks at how the drug moves through the body and whether it changes urine PC1 levels. Participants receive one dose and are followed for about three months. The focus is on safety and basic drug behavior, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ART105 (an experimental drug given as a single subcutaneous injection)
- What this could lead to
- If ART105 is safe and shows expected effects, it could pave the way for future studies in people with certain health conditions.
- What could go wrong
- This is an early, small trial in healthy volunteers, so results may not apply to patients. The drug may cause side effects or fail to show the desired effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test